Clinical trial results:
A Phase 3 Randomized Withdrawal, Double-blind, Placebo-controlled, Multi-center Study Investigating the Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over, With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Summary

EudraCT number	2018-000501-23
Trial protocol	BG NL BE PL DE LV SK ES IT
Global end of trial date	07 October 2020

Results information

Result version number	v1 (current)
This version publication date	09 April 2021
First version publication date	09 April 2021

Trial information

Trial identification

Sponsor protocol code	B7451014

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03627767
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final

Date of interim/final analysis	08 February 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	07 October 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate and compare the maintenance of effect of two doses of PF-04965842 (200 milligram [mg] and 100 mg once daily [QD]) and placebo in subjects aged 12 and above with moderate to severe atopic dermatitis (AD) who responded to initial open-label (OL) run-in treatment of 200 mg PF-04965842 QD.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	11 June 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Brazil: 55
Country: Number of subjects enrolled	Canada: 87
Country: Number of subjects enrolled	Chile: 77
Country: Number of subjects enrolled	China: 118
Country: Number of subjects enrolled	Argentina: 42
Country: Number of subjects enrolled	Israel: 8
Country: Number of subjects enrolled	Mexico: 28
Country: Number of subjects enrolled	Russian Federation: 99
Country: Number of subjects enrolled	Serbia: 12
Country: Number of subjects enrolled	Taiwan: 34
Country: Number of subjects enrolled	United States: 234
Country: Number of subjects enrolled	Belgium: 10
Country: Number of subjects enrolled	Bulgaria: 14
Country: Number of subjects enrolled	Germany: 54
Country: Number of subjects enrolled	Italy: 24
Country: Number of subjects enrolled	Latvia: 12
Country: Number of subjects enrolled	Netherlands: 13
Country: Number of subjects enrolled	Poland: 209
Country: Number of subjects enrolled	Romania: 3
Country: Number of subjects enrolled	Slovakia: 30
Country: Number of subjects enrolled	Spain: 72
Worldwide total number of subjects	1235
EEA total number of subjects	441

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	247
Adults (18-64 years)	943
From 65 to 84 years	45
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Total 1235 subjects were enrolled in 236 sites in 21 countries. Total 1233 subjects received the treatment, 2 subjects were randomised but not treated. Study started from 11 June 2018 and completed on 07 October 2020.

Period 1

Period 1 title	Open-label Run-in Period (12 Weeks)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	PF-04965842 200mg OL

Arm description:

Subjects received 12 weeks induction treatment of 200 mg oral tablets (each tablet of 100 mg) PF-04965842 QD during an open-label run-in period. Responders at the end of the 12-week open-label run-in period entered the 40 week, double-blind (DB), maintenance treatment period. Responder criteria was defined as a) achieving an Investigator's Global Assessment (IGA) of clear (0) or almost clear (1) (on a 5-point scale), b) a reduction from IGA baseline of greater than or equal to (>= 2) points, and c) reaching an Eczema Area and Severity Index-75 (EASI-75) response compared to baseline. Baseline was defined as the IGA score and EASI score obtained prior to dosing on Day 1. Non-responders had a choice to enroll into the PF-04965842 Long Term Extension (LTE) study B7451015 (NCT03422822) otherwise, they were permanently discontinued from treatment and were followed-up for 4-week in this study.

Arm type	Experimental
Investigational medicinal product name	PF-04965842 200 mg
Investigational medicinal product code	
Other name	Abrocitinib
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received 200 mg PF-04965842 (2 tablets of 100 mg each) orally QD.

Number of subjects in period 1[1]	PF-04965842 200mg OL
Started	1233
Completed	798
Not completed	435
Protocol deviation	11
Medication Error Without Associated Adverse Event	1
Withdrawal By Parent/Guardian	2
Lack of efficacy	315
Adverse event, serious fatal	1

Adverse event, non-fatal	48
Unspecified	4
Consent withdrawn by subject	40
Lost to follow-up	13

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
Justification: Baseline analysis was performed on Full analysis set open-label (FAS-OL) which included all subjects who received at least one dose of study medication during the open label run-in phase.

Period 2

Period 2 title	Double-blind Treatment Period (40 Weeks)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	PF-04965842 200mg OL to Placebo DB

Arm description:

Responders from open-label run-in period received two placebo tablets matched to PF-04965842 orally QD during DB period for up to 40 weeks. Subjects who met the protocol defined flare criteria entered in open-label rescue period (RP). Flare was defined as a loss of at least 50 % of the EASI response at Week 12 and an IGA score of 2 or higher.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received two placebo tablets matched to PF-04965842 orally QD.

Arm title	PF-04965842 200mg OL to 100mg DB

Arm description:

Responders from open-label run-in period received a tablet of 100 mg PF-04965842 and a tablet of matching placebo orally QD during DB period for up to 40 weeks. Subjects who met the protocol defined flare criteria entered in open-label rescue period. Flare was defined as a loss of at least 50 percent (%) of the EASI response at Week 12 and an IGA score of 2 or higher.

Arm type	Experimental
Investigational medicinal product name	PF-04965842 100 mg
Investigational medicinal product code	
Other name	Abrocitinib
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received 100 mg PF-04965842 tablet orally QD.

Arm title	PF-04965842 200mg OL to 200mg DB

Arm description:

Responders from open-label run-in period received 200 mg PF-04965842 (2 tablets of 100 mg each) orally QD during DB period for up to 40 weeks. Subjects who met the protocol defined flare criteria entered in open-label rescue period. Flare was defined as a loss of at least 50 % of the EASI response at Week 12 and an IGA score of 2 or higher.

Arm type	Experimental
Investigational medicinal product name	PF-04965842 200 mg
Investigational medicinal product code	
Other name	Abrocitinib
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received 200 mg PF-04965842 (2 tablets of 100 mg each) orally QD.

Number of subjects in period 2	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB
Started	267	265	266
Subjects entered rescue period	208 [2]	109 [3]	44 [4]
Completed after entering rescue period	201 [5]	99 [6]	41 [7]
Completed without entering rescue period	43 [8]	134 [9]	187 [10]
Completed	251	243	231
Not completed	16	22	35
Protocol deviation	1	5	2
Withdrawal By Parent/Guardian	-	1	-
Adverse event, non-fatal	6	7	19
Unspecified	-	1	1
Consent withdrawn by subject	9	6	10
Lost to follow-up	-	2	3

Notes:

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Subjects who met the protocol defined flare criteria entered in open-label rescue period.

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Subjects who met the protocol defined flare criteria entered in open-label rescue period.

[4] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Subjects who met the protocol defined flare criteria entered in open-label rescue period.

[5] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Subjects who met the protocol defined flare criteria entered in open-label rescue period.

[6] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Subjects who met the protocol defined flare criteria entered in open-label rescue period.

[7] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Subjects who met the protocol defined flare criteria entered in open-label rescue period.

[8] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Subjects who met the protocol defined flare criteria entered in open-label rescue period.

[9] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Subjects who met the protocol defined flare criteria entered in open-label rescue period.

[10] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Subjects who met the protocol defined flare criteria entered in open-label rescue period.

Period 3

Period 3 title	Open-label Rescue Period (12 Weeks)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	PF-04965842 200 mg Rescue Period

Arm description:

Subjects who met the protocol defined flare criteria in DB period received 200 mg PF-04965842 (2 tablets of 100 mg each) orally QD during OL Rescue Period for up to 12 weeks. After completing the 12-week rescue period, subjects had the choice to enter the LTE study B7451015 (NCT03422822), if eligible. Subjects who discontinued early from treatment, or who were otherwise ineligible for the LTE study entered were followed-up for 4 week in this study.

Arm type	Experimental
Investigational medicinal product name	PF-04965842 200 mg
Investigational medicinal product code	
Other name	Abrocitinib
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received 200 mg PF-04965842 (2 tablets of 100 mg each) orally QD.

Number of subjects in period 3[11]	PF-04965842 200 mg Rescue Period
Started	361
Met protocol-defined flare criteria	351
Completed	341
Not completed	20
Adverse event, non-fatal	9
Unspecified	1
Consent withdrawn by subject	9
Lost to follow-up	1

Notes:

[11] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
Justification: Subjects who met the protocol defined flare criteria entered in open-label rescue period.

Baseline characteristics

Reporting groups	
Reporting group title	PF-04965842 200mg OL

Reporting group description:

Subjects received 12 weeks induction treatment of 200 mg oral tablets (each tablet of 100 mg) PF-04965842 QD during an open-label run-in period. Responders at the end of the 12-week open-label run-in period entered the 40 week, double-blind (DB), maintenance treatment period. Responder criteria was defined as a) achieving an Investigator's Global Assessment (IGA) of clear (0) or almost clear (1) (on a 5-point scale), b) a reduction from IGA baseline of greater than or equal to (>= 2) points, and c) reaching an Eczema Area and Severity Index-75 (EASI-75) response compared to baseline. Baseline was defined as the IGA score and EASI score obtained prior to dosing on Day 1. Non-responders had a choice to enroll into the PF-04965842 Long Term Extension (LTE) study B7451015 (NCT03422822) otherwise, they were permanently discontinued from treatment and were followed-up for 4-week in this study.

Reporting group values	PF-04965842 200mg OL	Total	
Number of subjects	1233	1233	
Age Categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	246	246	
Adolescents (12-17 years)	942	942	
Adults (18-64 years)	45	45	
From 65-84 years	0	0	
85 years and over	0	0	
Gender Categorical Units: Subjects			
Female	684	684	
Male	549	549	
Race Units: Subjects			
White	931	931	
Black or African American	75	75	
Asian	196	196	
American Indian or Alaska Native	7	7	
Multiracial	17	17	
Not Reported	6	6	
Native Hawaiian or Other Pacific Islander	1	1	
Ethnicity Units: Subjects			
Hispanic or Latino	246	246	
Not Hispanic or Latino	981	981	
Unknown	1	1	
Not Reported	5	5	

End points

End points reporting groups

Reporting group title	PF-04965842 200mg OL

Reporting group description:

Subjects received 12 weeks induction treatment of 200 mg oral tablets (each tablet of 100 mg) PF-04965842 QD during an open-label run-in period. Responders at the end of the 12-week open-label run-in period entered the 40 week, double-blind (DB), maintenance treatment period. Responder criteria was defined as a) achieving an Investigator's Global Assessment (IGA) of clear (0) or almost clear (1) (on a 5-point scale), b) a reduction from IGA baseline of greater than or equal to (>= 2) points, and c) reaching an Eczema Area and Severity Index-75 (EASI-75) response compared to baseline. Baseline was defined as the IGA score and EASI score obtained prior to dosing on Day 1. Non-responders had a choice to enroll into the PF-04965842 Long Term Extension (LTE) study B7451015 (NCT03422822) otherwise, they were permanently discontinued from treatment and were followed-up for 4-week in this study.

Reporting group title	PF-04965842 200mg OL to Placebo DB

Reporting group description:

Responders from open-label run-in period received two placebo tablets matched to PF-04965842 orally QD during DB period for up to 40 weeks. Subjects who met the protocol defined flare criteria entered in open-label rescue period (RP). Flare was defined as a loss of at least 50 % of the EASI response at Week 12 and an IGA score of 2 or higher.

Reporting group title	PF-04965842 200mg OL to 100mg DB

Reporting group description:

Responders from open-label run-in period received a tablet of 100 mg PF-04965842 and a tablet of matching placebo orally QD during DB period for up to 40 weeks. Subjects who met the protocol defined flare criteria entered in open-label rescue period. Flare was defined as a loss of at least 50 percent (%) of the EASI response at Week 12 and an IGA score of 2 or higher.

Reporting group title	PF-04965842 200mg OL to 200mg DB

Reporting group description:

Responders from open-label run-in period received 200 mg PF-04965842 (2 tablets of 100 mg each) orally QD during DB period for up to 40 weeks. Subjects who met the protocol defined flare criteria entered in open-label rescue period. Flare was defined as a loss of at least 50 % of the EASI response at Week 12 and an IGA score of 2 or higher.

Reporting group title	PF-04965842 200 mg Rescue Period

Reporting group description:

Subjects who met the protocol defined flare criteria in DB period received 200 mg PF-04965842 (2 tablets of 100 mg each) orally QD during OL Rescue Period for up to 12 weeks. After completing the 12-week rescue period, subjects had the choice to enter the LTE study B7451015 (NCT03422822), if eligible. Subjects who discontinued early from treatment, or who were otherwise ineligible for the LTE study entered were followed-up for 4 week in this study.

Primary: Percentage of Subjects With Loss of Response: Double-blind (DB) Period

End point title	Percentage of Subjects With Loss of Response: Double-blind (DB) Period[1]

End point description:

Loss of response was denoted as flare and was defined as loss of at least 50% of EASI response at Week 12 and an Investigator's Global Assessment (IGA) score of 2 or higher. EASI quantifies severity of subject's atopic dermatitis (AD) based on both severity of lesion clinical signs and % of body surface area (BSA) affected. EASI is a composite scoring by AD clinical evaluator of degree of erythema, induration/papulation, excoriation, and lichenification for each of 4 body regions. IGA assesses severity of AD on 5-point scale (0-4, higher scores=more severity), reflecting global consideration of erythema, induration and scaling. Where, 0=clear; 1=almost clear; 2=mild; 3=moderate,; 4=severe. Missing event times were considered as right censored (censored at random [CAR]) on last date of randomised treatment. Full analysis set-randomised (FAS-RA) included as all subjects who were randomised at Week 12 and received at least 1 dose of study medication within DB phase.

End point type	Primary

End point timeframe:

Up to Week 40

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be analysed for this endpoint.

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	267	265	266	
Units: percentage of subjects				
number (not applicable)	77.5	39.6	16.5	

Statistical analyses

No statistical analyses for this end point

Primary: Time to Loss of Response: Double-blind Period

End point title	Time to Loss of Response: Double-blind Period

End point description:

Time to loss of response based on achieving IGA >=2 was measured from date of first dose of randomised treatment until last dose of randomised treatment (if not entered rescue) or first day of rescue treatment (if entered rescue) and based on EASI, loss of at least 50% of EASI response at Week 12. IGA assesses severity of AD on 5-point scale (0-4, higher scores=more severity), reflecting global consideration of erythema, induration and scaling with scores 0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe. EASI quantifies severity of AD based on severity of lesion clinical signs and % of BSA affected. EASI composite score evaluates degree of erythema, induration/papulation, excoriation, and lichenification. FAS-RA population was analysed. Missing event times were considered as right censored (CAR) on last date of randomised treatment. Number of Subjects Analysed=number of subjects evaluable for this endpoint. 99999=data was not evaluable as too few events were observed.

End point type	Primary

End point timeframe:

Up to Week 40

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	207	105	44	
Units: days				
median (confidence interval 95%)	28.0 (28.0 to 29.0)	323.0 (282.0 to 323.0)	99999 (99999 to 99999)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

A Cox regression model with treatment, age group and disease severity as stratification covariates was used to estimate the hazard ratio and the corresponding 95 percent (%) confidence interval (CI).

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [2]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.27
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.211
upper limit	0.341

Notes:

[2] - A stratified log-rank test with age group and disease severity as stratification variables was performed to evaluate P value.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

A Cox regression model with treatment, age group and disease severity as stratification covariates was used to estimate the hazard ratio and the corresponding 95% CI.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	251
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [3]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.07
upper limit	0.136

Notes:

[3] - A stratified log-rank test with age group and disease severity as stratification variables was performed to evaluate P value.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

A Cox regression model with treatment, age group and disease severity as stratification covariates was used to estimate the hazard ratio and the corresponding 95% CI.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	149
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [4]
Method	Logrank
Parameter estimate	Hazard ratio (HR)

Point estimate	0.36
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.255
upper limit	0.516

Notes:

[4] - A stratified log-rank test with age group and disease severity as stratification variables was performed to evaluate P value.

Secondary: Time to First Loss of Response Based on Investigator's Global Assessment (IGA) Score of 2 or Higher: Double-blind Period

End point title	Time to First Loss of Response Based on Investigator's Global Assessment (IGA) Score of 2 or Higher: Double-blind Period

End point description:

Time to loss of response based on achieving IGA >=2 (for the first time) as measured from date of first dose of randomised treatment until the last dose of randomised treatment (if not entered rescue) or first day of rescue treatment (if entered rescue). IGA assesses severity of atopic dermatitis (AD) on a 5-point scale (0-4, higher scores indicated more severity), reflecting global consideration of erythema, induration and scaling. Where, 0=clear, AD is cleared; 1=almost clear, AD not entirely cleared, light pink residual lesions; 2=mild, AD with light red lesions; 3=moderate, AD with red lesions; 4=severe, AD with deep, dark red lesions. Missing event times were considered as right censored (CAR) on the last date of randomised treatment. FAS-RA included as all subjects who were randomised at Week 12 and received at least one dose of study medication within the double-blind phase. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:

From date of first dose of randomised treatment until the last dose of randomised treatment (if not entered rescue) or first day of rescue treatment (if entered rescue) (maximum up to week 40)

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	247	183	145	
Units: days				
median (confidence interval 95%)	27.0 (26.0 to 28.0)	78.0 (32.0 to 112.0)	201.0 (177.0 to 282.0)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

A Cox regression model with treatment, age group and disease severity as stratification covariates was used to estimate the hazard ratio and the corresponding 95% CI.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	430
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [5]
Method	Logrank

Parameter estimate	Hazard ratio (HR)
Point estimate	0.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.286
upper limit	0.424

Notes:

[5] - A stratified log-rank test with age group and disease severity as stratification variables was performed to evaluate P value.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

A Cox regression model with treatment, age group and disease severity as stratification covariates was used to estimate the hazard ratio and the corresponding 95% CI.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	392
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [6]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.176
upper limit	0.27

Notes:

[6] - A stratified log-rank test with age group and disease severity as stratification variables was performed to evaluate P value.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

A Cox regression model with treatment, age group and disease severity as stratification covariates was used to estimate the hazard ratio and the corresponding 95% CI.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	328
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [7]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.63
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.503
upper limit	0.78

Notes:

[7] - A stratified log-rank test with age group and disease severity as stratification variables was performed to evaluate P value.

Secondary: Percentage of Subjects Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and a Reduction of Greater Than or Equal to (>=) 2 Points From Baseline at Weeks 12, 16, 28, 40, and 52: Double-blind Period

End point title	Percentage of Subjects Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and a Reduction of Greater Than or Equal to (>=) 2 Points From Baseline at Weeks 12, 16, 28, 40, and 52: Double-blind Period

End point description:

IGA assessed severity of atopic dermatitis (AD) on a 5-point scale (0-4, higher scores indicated more severity), reflecting global consideration of erythema, induration and scaling. Where, 0=clear, no inflammatory signs of AD; 1=almost clear, AD not fully cleared, light pink residual lesions; 2=mild, AD with light red lesions; 3=moderate, AD with red lesions; 4=severe, AD with deep dark red lesions. FAS-RA included as all subjects who were randomised at Week 12 and received at least 1 dose of study medication within DB phase. 'Number of Subjects Analysed'= subjects evaluable for this endpoint and 'n' = number of subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	267	264	266	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 12 (n= 266, 264, 265)	99.6 (98.9 to 100.0)	99.6 (98.9 to 100.0)	99.2 (98.2 to 100.0)	
Week 16 (n= 267, 263, 266)	15.4 (11.0 to 19.7)	55.5 (49.5 to 61.5)	77.8 (72.8 to 82.8)	
Week 28 (n= 267, 260, 262)	10.5 (6.8 to 14.2)	45.0 (39.0 to 51.0)	61.8 (55.9 to 67.7)	
Week 40 (n= 265, 260, 259)	10.6 (6.9 to 14.3)	42.3 (36.3 to 48.3)	57.1 (51.1 to 63.2)	
Week 52 (n= 264, 258, 257)	11.7 (7.9 to 15.6)	36.8 (30.9 to 42.7)	54.1 (48.0 to 60.2)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531

Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9495 [8]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	1.1

Notes:

[8] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5717 [9]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6
upper limit	0.9

Notes:

[9] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.7

upper limit	0.9

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [10]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	40.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	33.1
upper limit	47.8

Notes:

[10] - P-value was adjusted by disease severity at baseline and randomisation strata

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [11]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	62.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	56.1
upper limit	69.2

Notes:

[11] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal

approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	22.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	14.3
upper limit	29.9

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [12]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	35.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	28.1
upper limit	42

Notes:

[12] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [13]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	51.5
Confidence interval	

level	95 %
sides	2-sided
lower limit	44.6
upper limit	58.4

Notes:

[13] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	16.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.1
upper limit	24.8

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [14]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	32.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	25.2
upper limit	39.2

Notes:

[14] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based

on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [15]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	46.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	39.9
upper limit	53.8

Notes:

[15] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	14.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.9
upper limit	22.6

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [16]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	25.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	18.5
upper limit	32.5

Notes:

[16] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [17]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	42.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	35.3
upper limit	49.7

Notes:

[17] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	17.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.6
upper limit	25.5

Secondary: Percentage of Subjects Achieving Eczema Area and Severity Index (EASI) Response >=50% Improvement From Baseline at Weeks 12, 16, 28, 40 and

52: Double-blind Period

End point title	Percentage of Subjects Achieving Eczema Area and Severity Index (EASI) Response >=50% Improvement From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

EASI quantifies severity of subject's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema [E], induration/papulation [I], excoriation [Ex] and lichenification [L]) scored separately for each of 4 body regions (head and neck [h], upper limbs [u], trunk [t] [including axillae and groin] and lower limbs [l] [including buttocks]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (>0 to <10%), 2 (10 to <30%), 3 (30 to <50%), 4 (50 to <70%), 5 (70 to <90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll); A=area score. Total EASI score ranged from 0.0 to 72.0, higher scores=greater severity of AD. FAS-RA population analysed. Number of Subjects Analysed=subjects evaluable for this endpoint and n=subjects evaluable for specified time points.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	267	264	266	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 12 (n= 266, 264, 265)	100.0 (98.6 to 100.0)	100.0 (98.6 to 100.0)	100.0 (98.6 to 100.0)	
Week 16 (n= 267, 263, 266)	40.8 (34.9 to 46.7)	83.3 (78.8 to 87.8)	96.2 (94.0 to 98.5)	
Week 28 (n= 267, 260, 262)	22.8 (17.8 to 27.9)	68.1 (62.4 to 73.7)	85.9 (81.7 to 90.1)	
Week 40 (n= 265, 260, 259)	16.6 (12.1 to 21.1)	57.3 (51.3 to 63.3)	74.9 (69.6 to 80.2)	
Week 52 (n= 264, 258, 257)	15.9 (11.5 to 20.3)	50.8 (44.7 to 56.9)	71.2 (65.7 to 76.7)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage

Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	0

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions. P-value was adjusted by disease severity at baseline and randomisation strata.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	0

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	0

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [18]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	42.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	35.3
upper limit	50.1

Notes:

[18] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [19]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	55.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	49.1
upper limit	61.7

Notes:

[19] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority

Parameter estimate	Difference in percentage
Point estimate	12.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.9
upper limit	17.9

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [20]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	45.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	37.9
upper limit	53

Notes:

[20] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [21]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	63
Confidence interval	
level	95 %
sides	2-sided
lower limit	56.4
upper limit	69.5

Notes:

[21] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	17.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.7
upper limit	24.7

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [22]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	41
Confidence interval	
level	95 %
sides	2-sided
lower limit	33.6
upper limit	48.5

Notes:

[22] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB

Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [23]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	58.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	51.3
upper limit	65.2

Notes:

[23] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	17.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.6
upper limit	25.5

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [24]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	35.3
Confidence interval	
level	95 %
sides	2-sided

lower limit	27.8
upper limit	42.8

Notes:

[24] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001 [25]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	55.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	48.3
upper limit	62.4

Notes:

[25] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	20.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.1
upper limit	28.5

Secondary: Percentage of Subjects Achieving Eczema Area and Severity Index (EASI) Response >=75% Improvement From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point title	Percentage of Subjects Achieving Eczema Area and Severity Index (EASI) Response >=75% Improvement From Baseline at

	Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

EASI quantifies severity of subject's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin] and lower limbs [including buttocks]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (>0 to <10%), 2 (10 to <30%), 3 (30 to <50%), 4 (50 to <70%), 5 (70 to <90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll). Total EASI score ranged from 0.0 to 72.0, higher scores=greater severity of AD. FAS-RA population analysed. Number of Subjects Analysed=subjects evaluable for this endpoint and n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	267	264	266	
Units: percentage of Subjects				
number (confidence interval 95%)				
Week 12 (n= 266, 264, 265)	99.2 (98.2 to 100.0)	100.0 (98.6 to 100.0)	99.6 (98.9 to 100.0)	
Week 16 (n= 267, 263, 266)	27.0 (21.6 to 32.3)	76.0 (70.9 to 81.2)	92.5 (89.3 to 95.7)	
Week 28 (n= 267, 260, 262)	18.0 (13.4 to 22.6)	60.4 (54.4 to 66.3)	80.5 (75.7 to 85.3)	
Week 40 (n= 265, 260, 259)	15.1 (10.8 to 19.4)	54.2 (48.2 to 60.3)	71.8 (66.3 to 77.3)	
Week 52 (n= 264, 258, 257)	14.0 (9.8 to 18.2)	46.5 (40.4 to 52.6)	65.8 (60.0 to 71.6)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1848 [26]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	0.7
Confidence interval	
level	95 %

sides	2-sided
lower limit	-0.3
upper limit	1.7

Notes:

[26] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5971 [27]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.9
upper limit	1.6

Notes:

[27] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1
upper limit	0.4

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline

using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [28]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	49.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	42
upper limit	56.8

Notes:

[28] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [29]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	65.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	59.3
upper limit	71.7

Notes:

[29] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage

Point estimate	16.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.3
upper limit	22.3

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [30]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	42.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	35.2
upper limit	50.2

Notes:

[30] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [31]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	62.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	56
upper limit	69.2

Notes:

[31] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	19.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.3
upper limit	27.4

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [32]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	39.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	32.1
upper limit	46.9

Notes:

[32] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB

Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [33]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	56.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	49.8
upper limit	63.7

Notes:

[33] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	17.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.3
upper limit	25.5

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [34]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	33
Confidence interval	
level	95 %
sides	2-sided

lower limit	25.7
upper limit	40.4

Notes:

[34] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [35]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	51.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	44.6
upper limit	58.8

Notes:

[35] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	19.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.8
upper limit	27.6

Secondary: Percentage of Subjects Achieving Eczema Area and Severity index (EASI) Response >=90% Improvement From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point title	Percentage of Subjects Achieving Eczema Area and Severity index (EASI) Response >=90% Improvement From Baseline at

	Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

EASI quantifies severity of subject's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin] and lower limbs [including buttocks]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (>0 to <10%), 2 (10 to <30%), 3 (30 to <50%), 4 (50 to <70%), 5 (70 to <90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll). Total EASI score ranged from 0.0 to 72.0, higher scores=greater severity of AD. FAS-RA population analysed. Number of Subjects Analysed=subjects evaluable for this endpoint and n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	267	264	266	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 12 (n= 266, 264, 265)	84.6 (80.2 to 88.9)	87.1 (83.1 to 91.2)	86.4 (82.3 to 90.5)	
Week 16 (n= 267, 263, 266)	13.9 (9.7 to 18.0)	51.3 (45.3 to 57.4)	77.1 (72.0 to 82.1)	
Week 28 (n= 267, 260, 262)	10.5 (6.8 to 14.2)	46.9 (40.9 to 53.0)	64.5 (58.7 to 70.3)	
Week 40 (n= 265, 260, 259)	12.1 (8.2 to 16.0)	41.5 (35.5 to 47.5)	58.7 (52.7 to 64.7)	
Week 52 (n= 264, 258, 257)	10.6 (6.9 to 14.3)	37.6 (31.7 to 43.5)	54.5 (48.4 to 60.6)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3994 [36]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	2.6
Confidence interval	
level	95 %

sides	2-sided
lower limit	-3.3
upper limit	8.4

Notes:

[36] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5542 [37]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.1
upper limit	7.8

Notes:

[37] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.5
upper limit	5

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline

using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [38]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	37.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	30.2
upper limit	44.9

Notes:

[38] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [39]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	63.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	56.8
upper limit	69.8

Notes:

[39] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage

Point estimate	25.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	17.7
upper limit	33.4

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [40]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	36.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	29.9
upper limit	44

Notes:

[40] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [41]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	54.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	47.3
upper limit	61

Notes:

[41] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	17.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.9
upper limit	25.5

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [42]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	29.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	22.7
upper limit	37

Notes:

[42] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB

Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [43]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	46.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	39.6
upper limit	53.8

Notes:

[43] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	16.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.5
upper limit	25.3

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [44]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	27.4
Confidence interval	
level	95 %
sides	2-sided

lower limit	20.4
upper limit	34.3

Notes:

[44] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [45]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	43.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	36.7
upper limit	50.9

Notes:

[45] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	16.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.4
upper limit	25.2

Secondary: Percentage of Subjects Achieving Eczema Area and Severity index (EASI) Response >=100% Improvement From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point title	Percentage of Subjects Achieving Eczema Area and Severity index (EASI) Response >=100% Improvement From Baseline

	at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

EASI quantifies severity of subject's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin] and lower limbs [including buttocks]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (>0 to <10%), 2 (10 to <30%), 3 (30 to <50%), 4 (50 to <70%), 5 (70 to <90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll). Total EASI score ranged from 0.0 to 72.0, higher scores=greater severity of AD. FAS-RA population analysed. Number of Subjects Analysed=subjects evaluable for this endpoint and n=subjects evaluable for the specified time point.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	267	264	266	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 12 (n= 266, 264, 265)	30.5 (24.9 to 36.0)	30.3 (24.8 to 35.8)	28.3 (22.9 to 33.7)	
Week 16 (n= 267, 263, 266)	3.7 (1.5 to 6.0)	15.2 (10.9 to 19.5)	28.9 (23.5 to 34.4)	
Week 28 (n= 267, 260, 262)	4.1 (1.7 to 6.5)	16.5 (12.0 to 21.1)	30.2 (24.6 to 35.7)	
Week 40 (n= 265, 260, 259)	4.5 (2.0 to 7.0)	15.8 (11.3 to 20.2)	30.1 (24.5 to 35.7)	
Week 52 (n= 264, 258, 257)	4.5 (2.0 to 7.1)	18.6 (13.9 to 23.4)	28.8 (23.3 to 34.3)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9313 [46]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	0.3
Confidence interval	
level	95 %

sides	2-sided
lower limit	-7.5
upper limit	8.1

Notes:

[46] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6043 [47]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	-2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.8
upper limit	5.7

Notes:

[47] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	-2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10
upper limit	5.4

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline

using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [48]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	11.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.6
upper limit	16.5

Notes:

[48] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [49]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	25.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	19.4
upper limit	31.2

Notes:

[49] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage

Point estimate	13.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.6
upper limit	20.4

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [50]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	12.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.7
upper limit	18

Notes:

[50] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [51]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	26
Confidence interval	
level	95 %
sides	2-sided
lower limit	19.9
upper limit	32

Notes:

[51] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	13.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.3
upper limit	20.6

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [52]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	11.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.5
upper limit	16.8

Notes:

[52] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB

Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [53]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	25.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	19.6
upper limit	31.8

Notes:

[53] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	14.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	7
upper limit	21.2

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	531
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [54]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	14.6
Confidence interval	
level	95 %
sides	2-sided

lower limit	9.2
upper limit	20

Notes:

[54] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [55]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	24.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.4
upper limit	30.5

Notes:

[55] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	10
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.7
upper limit	17.2

Secondary: Percentage of Subjects With Greater Than or Equal 4 Points Improvement in the Numerical Rating Scale (NRS) for Severity of Pruritus From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point title	Percentage of Subjects With Greater Than or Equal 4 Points Improvement in the Numerical Rating Scale (NRS) for Severity

	of Pruritus From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

Subjects were asked to assess their itch at the worst moment over the past 24 hours on an NRS scale ranged from 0 (no itch) to 10 (worst itch imaginable), where higher scores indicated greater severity. FAS-RA included as all subjects who were randomised at Week 12 and received at least one dose of study medication within the DB phase. Here 'Number of Subjects Analysed' signifies subjects evaluable for this endpoint and 'n' signifies number of subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	258	254	250	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 12 (n= 230, 237, 232)	82.2 (77.2 to 87.1)	84.0 (79.3 to 88.6)	81.9 (76.9 to 86.9)	
Week 16 (n= 252, 251, 250)	15.9 (11.4 to 20.4)	54.6 (48.4 to 60.7)	75.6 (70.3 to 80.9)	
Week 28 (n= 258, 251, 245)	11.6 (7.7 to 15.5)	45.0 (38.9 to 51.2)	66.9 (61.0 to 72.8)	
Week 40 (n= 257, 254, 246)	10.1 (6.4 to 13.8)	39.4 (33.4 to 45.4)	55.7 (49.5 to 61.9)	
Week 52 (n= 252, 216, 204)	8.3 (4.9 to 11.7)	27.3 (21.4 to 33.3)	49.0 (42.2 to 55.9)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	512
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6082 [56]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5
upper limit	8.5

Notes:

[56] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.964 [57]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.7
upper limit	7

Notes:

[57] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	504
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	-2.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.1
upper limit	4.4

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB

Number of subjects included in analysis	512
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [58]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	38.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	31.2
upper limit	46.5

Notes:

[58] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [59]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	59.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	52.7
upper limit	66.7

Notes:

[59] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	504
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	20.9
Confidence interval	
level	95 %
sides	2-sided

lower limit	12.7
upper limit	29

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	512
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [60]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	33.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	26.6
upper limit	41.2

Notes:

[60] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [61]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	55.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	48.2
upper limit	62.3

Notes:

[61] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage and CI for difference were calculated based on the weighted average

of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	504
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	21.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	13.2
upper limit	30.2

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	512
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [62]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	29.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	22.7
upper limit	36.7

Notes:

[62] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [63]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	45.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	38.4
upper limit	52.7

Notes:

[63] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	504
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	16
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.4
upper limit	24.6

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	512
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [64]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	19.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.7
upper limit	26.4

Notes:

[64] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [65]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	40.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	32.8
upper limit	48.1

Notes:

[65] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	504
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	21.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.1
upper limit	30.3

Secondary: Percent Change From Baseline in Body Surface Area (BSA) at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point title	Percent Change From Baseline in Body Surface Area (BSA) at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

4 body regions evaluated: head and neck, upper limbs, trunk (including axillae, groin/genitals), lower limbs (including buttocks) excluding scalp, palms, soles. BSA calculated by handprint method. Number (No) of handprints (size of subject's hand with fingers in closed position) fitting in affected area of a body region was estimated. Maximum No of handprints were 10, 20, 30, 40 for head and neck, upper limbs, trunk, and lower limbs respectively. Surface area (SA) of body region equivalent to 1 handprint: 1 handprint=10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. %Change BSA for a body region was calculated as=total No of handprints in a body region* %SA equivalent to 1 handprint. %BSA for an individual: arithmetic mean of %BSA of all 4 body regions, ranged from 0-100%, higher values=greater AD severity. FAS-RA population analysed. Number of Subjects Analysed=subjects evaluable for this endpoint and n=subjects evaluable for specified time

points.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	266	264	265	
Units: percent change in BSA				
median (inter-quartile range (Q1-Q3))				
Change at Week 12 (n= 266, 264, 265)	-95.6 (-100.0 to -88.5)	-96.7 (-100.0 to -91.5)	-96.7 (-100.0 to -89.2)	
Change at Week 16 (n= 135, 223, 256)	-68.5 (-89.8 to -37.5)	-90.9 (-97.6 to -78.3)	-96.3 (-100.0 to -88.7)	
Change at Week 28 (n= 64, 180, 227)	-85.2 (-95.8 to -63.5)	-93.8 (-99.5 to -81.4)	-96.4 (-100.0 to -85.7)	
Change at Week 40 (n= 46, 151, 197)	-91.2 (-100.0 to -77.9)	-95.8 (-100.0 to -83.5)	-96.8 (-100.0 to -88.8)	
Change at Week 52 (n= 42, 134, 185)	-91.5 (-100.0 to -77.9)	-96.9 (-100.0 to -83.4)	-96.9 (-100.0 to -88.2)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Total Score at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point title	Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Total Score at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3); severity scores added to give B (0-18). C: pruritus and sleep loss, each of these 2 were scored by subject/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7*B/2+C; range (0-103); higher values=worse outcome. FAS-RA was analysed. Number of Subjects Analysed=subjects evaluable for endpoint and n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	265	264	265	
Units: percent change in SCORAD total score				
median (inter-quartile range (Q1-Q3))				
Change at Week 12 (n= 265, 264, 265)	-84.0 (-94.7 to -73.5)	-84.4 (-95.2 to -74.9)	-84.4 (-93.8 to -74.2)	
Change at Week 16 (n= 134, 224, 256)	-50.4 (-68.3 to -32.1)	-71.7 (-87.8 to -60.5)	-83.6 (-95.1 to -70.6)	
Change at Week 28 (n= 62, 177, 227)	-63.4 (-81.9 to -48.3)	-77.8 (-90.2 to -62.6)	-83.8 (-97.4 to -66.4)	
Change at Week 40 (n= 46, 152, 196)	-74.4 (-89.5 to -60.6)	-77.1 (-94.1 to -64.3)	-84.6 (-98.6 to -68.4)	
Change at Week 52 (n= 43, 132, 184)	-73.3 (-89.8 to -58.0)	-82.5 (-97.7 to -64.1)	-83.2 (-100.0 to -69.1)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analogue Scale (VAS) of Itch and Sleep Loss at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point title	Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analogue Scale (VAS) of Itch and Sleep Loss at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region-head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by subject/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7*B/2+C; range (0-103); higher values=worse outcome. FAS-RA was analysed. Number of Subjects Analysed=subjects evaluable for endpoint and n=subjects evaluable at the specified time point.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	264	264	261	
Units: units on a scale				
least squares mean (confidence interval 95%)				

Pruritus VAS: Change at Week 12 (n=264, 264, 261)	-6.1 (-6.3 to -5.9)	-6.1 (-6.3 to -5.9)	-6.1 (-6.3 to -5.9)	
Pruritus VAS: Change at Week 16 (n=264, 264, 261)	3.4 (3.0 to 3.7)	1.2 (1.0 to 1.5)	0.2 (-0.1 to 0.4)	
Pruritus VAS: Change at Week 28 (n=264, 264, 261)	2.4 (1.9 to 2.9)	1.1 (0.8 to 1.4)	0.5 (0.3 to 0.8)	
Pruritus VAS: Change at Week 40 (n=264, 264, 261)	2.2 (1.6 to 2.8)	1.2 (0.9 to 1.6)	0.4 (0.1 to 0.7)	
Pruritus VAS: Change at Week 52 (n=264, 264, 261)	1.8 (1.2 to 2.4)	1.3 (0.9 to 1.6)	0.5 (0.2 to 0.8)	
Sleep Loss VAS: Change at Week 12 (n=264,264,260)	-5.0 (-5.2 to -4.8)	-5.0 (-5.2 to -4.8)	-5.1 (-5.3 to -4.9)	
Sleep Loss VAS: Change at Week 16 (n=264,264,260)	2.3 (2.0 to 2.6)	0.5 (0.3 to 0.8)	0.0 (-0.2 to 0.2)	
Sleep Loss VAS: Change at Week 28 (n=264,264,260)	1.3 (0.9 to 1.7)	0.6 (0.4 to 0.9)	0.2 (0.0 to 0.4)	
Sleep Loss VAS: Change at Week 40 (n=264,264,260)	1.3 (0.8 to 1.8)	0.6 (0.3 to 0.9)	0.2 (0.0 to 0.4)	
Sleep Loss VAS: Change at Week 52 (n=264,264,260)	1.2 (0.7 to 1.8)	0.9 (0.5 to 1.2)	0.3 (0.0 to 0.5)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Pruritus VAS: Week 12: The least squares mean (LSM) differences between treatment groups were derived from the statistical model. Mixed model repeated measure (MMRM) contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9207
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	0.3

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Pruritus VAS: Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525

Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9998
Method	Mixed models analysis
Parameter estimate	LSM differences
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	0.3

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Pruritus VAS: Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM differences
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	0.3

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Pruritus VAS: Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM differences
Point estimate	-2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5

upper limit	-1.7

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB
Statistical analysis description:	
Pruritus VAS: Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM differences
Point estimate	-3.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.6
upper limit	-2.8

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB
Statistical analysis description:	
Pruritus VAS: Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM differences
Point estimate	-1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	-0.7

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB
Statistical analysis description:	
Pruritus VAS: Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg

	OL to 100mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM differences
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2
upper limit	-0.8

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB
Statistical analysis description:	
Pruritus VAS: Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	-1.3

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB
Statistical analysis description:	
Pruritus VAS: Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.5
Confidence interval	
level	95 %

sides	2-sided
lower limit	-0.9
upper limit	-0.1

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Pruritus VAS: Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0039
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.7
upper limit	-0.3

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Pruritus VAS: Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	-1.2

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Pruritus VAS: Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	-0.4

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Pruritus VAS: Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1488
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	0.2

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Pruritus VAS: Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0003
Method	Mixed models analysis
Parameter estimate	LSM difference

Point estimate	-1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2
upper limit	-0.6

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Pruritus VAS: Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	-0.3

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Sleep Loss VAS: Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9294
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	0.2

	Placebo DB vs PF-04965842 200mg DB

Statistical analysis title	
Statistical analysis description:	
Sleep Loss VAS: Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4081
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	0.1

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB
Statistical analysis description:	
Sleep Loss VAS: Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	0.1

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB
Statistical analysis description:	
Sleep Loss VAS: Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001

Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.1
upper limit	-1.4

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Sleep Loss VAS: Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	-2

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Sleep Loss VAS: Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.9
upper limit	-0.2

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Sleep Loss VAS: Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0035
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	-0.2

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Sleep Loss VAS: Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6
upper limit	-0.7

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Sleep Loss VAS: Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	-0.1

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Sleep Loss VAS: Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0136
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	-0.1

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Sleep Loss VAS: Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1.1
Confidence interval	
level	95 %

sides	2-sided
lower limit	-1.6
upper limit	-0.6

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Sleep Loss VAS: Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	0

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Sleep Loss VAS: Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2887
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	0.3

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Sleep Loss VAS: Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction,

baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0025
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6
upper limit	-0.3

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Sleep Loss VAS: Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	-0.2

Secondary: Percentage of Subjects With >=50% Improvement From Baseline in Scoring Atopic Dermatitis (SCORAD) Response at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point title	Percentage of Subjects With >=50% Improvement From Baseline in Scoring Atopic Dermatitis (SCORAD) Response at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by subject/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7*B/2+C; range (0-103); higher values=worse outcome. FAS-RA was analysed. Number of Subjects Analysed = subjects evaluable for this endpoint and n=subjects evaluable at the

specified time points.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	266	264	266	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 12 (n= 265, 264, 265)	97.4 (95.4 to 99.3)	98.5 (97.0 to 100.0)	97.0 (94.9 to 99.0)	
Week 16 (n= 266, 264, 266)	25.6 (20.3 to 30.8)	72.0 (66.6 to 77.4)	89.1 (85.4 to 92.8)	
Week 28 (n= 266, 259, 263)	15.8 (11.4 to 20.2)	56.8 (50.7 to 62.8)	75.7 (70.5 to 80.9)	
Week 40 (n= 264, 260, 258)	14.4 (10.2 to 18.6)	51.2 (45.1 to 57.2)	69.0 (63.3 to 74.6)	
Week 52 (n= 264, 258, 257)	14.8 (10.5 to 19.1)	44.6 (38.5 to 50.6)	65.8 (60.0 to 71.6)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4244 [66]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	3.4

Notes:

[66] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	532
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8092 [67]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.1
upper limit	2.4

Notes:

[67] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	-1.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.1
upper limit	1

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [68]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage

Point estimate	46.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	39.2
upper limit	54.2

Notes:

[68] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	532
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [69]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	63.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	57.2
upper limit	70

Notes:

[69] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	17
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.4
upper limit	23.5

	Placebo DB vs PF-04965842 100mg DB

Statistical analysis title	

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [70]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	41.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	33.9
upper limit	48.7

Notes:

[70] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	532
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [71]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	59.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	53.1
upper limit	66.7

Notes:

[71] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified

Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	18.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.8
upper limit	26.6

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [72]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	37
Confidence interval	
level	95 %
sides	2-sided
lower limit	29.6
upper limit	44.4

Notes:

[72] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	532
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [73]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	54.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	47.6
upper limit	61.7

Notes:

[73] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	17.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.4
upper limit	26

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [74]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	30
Confidence interval	
level	95 %
sides	2-sided
lower limit	22.6
upper limit	37.4

Notes:

[74] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB

Number of subjects included in analysis	532
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [75]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	50.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	43.8
upper limit	58.1

Notes:

[75] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	21.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.8
upper limit	29.5

Secondary: Percentage of Subjects With >=75% Improvement From Baseline in Scoring Atopic Dermatitis (SCORAD) Response at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point title	Percentage of Subjects With >=75% Improvement From Baseline in Scoring Atopic Dermatitis (SCORAD) Response at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by subject/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7*B/2+C; range (0-103); higher values=worse outcome. FAS-RA was analysed. Number of Subjects Analysed=subjects evaluable for endpoint and n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	266	264	266	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 12 (n= 265, 264, 265)	73.6 (68.3 to 78.9)	75.0 (69.8 to 80.2)	71.3 (65.9 to 76.8)	
Week 16 (n= 266, 264, 266)	9.4 (5.9 to 12.9)	38.3 (32.4 to 44.1)	67.3 (61.7 to 72.9)	
Week 28 (n= 266, 259, 263)	7.5 (4.3 to 10.7)	37.8 (31.9 to 43.7)	56.3 (50.3 to 62.3)	
Week 40 (n= 264, 260, 258)	8.3 (5.0 to 11.7)	32.7 (27.0 to 38.4)	47.7 (41.6 to 53.8)	
Week 52 (n= 264, 258, 257)	7.6 (4.4 to 10.8)	31.8 (26.1 to 37.5)	45.9 (39.8 to 52.0)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7232 [76]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.1
upper limit	8.8

Notes:

[76] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg

	OL to 200mg DB
Number of subjects included in analysis	532
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5694 [77]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	-2.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.8
upper limit	5.4

Notes:

[77] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	-3.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.2
upper limit	3.8

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [78]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	29
Confidence interval	
level	95 %

sides	2-sided
lower limit	22.2
upper limit	35.8

Notes:

[78] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	532
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [79]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	57.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	51.2
upper limit	64.5

Notes:

[79] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	28.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	20.8
upper limit	37

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline

using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [80]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	30.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	23.9
upper limit	37.2

Notes:

[80] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	532
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [81]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	48.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	42.1
upper limit	55.6

Notes:

[81] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage

Point estimate	18.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.8
upper limit	26.6

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [82]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	25
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.4
upper limit	31.5

Notes:

[82] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	532
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [83]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	39.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	32.7
upper limit	46.5

Notes:

[83] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	14.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.3
upper limit	22.8

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [84]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	24.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.1
upper limit	31.2

Notes:

[84] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB

Number of subjects included in analysis	532
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [85]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	38.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	31.6
upper limit	45.3

Notes:

[85] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	13.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.6
upper limit	22.3

Secondary: Percentage of Subjects Achieving IGA Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Rescue Baseline at Rescue Weeks 2, 4, 8 and 12: Rescue Period

End point title	Percentage of Subjects Achieving IGA Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Rescue Baseline at Rescue Weeks 2, 4, 8 and 12: Rescue Period

End point description:

IGA assessed severity of AD on a 5-point scale (0-4, higher scores indicated more severity), reflecting global consideration of erythema, induration and scaling. Where, 0=clear, AD is cleared; 1 = almost clear, AD not entirely cleared, light pink residual lesions; 2 = mild, AD with light red lesions; 3 = moderate, AD with red lesions; 4 = severe, AD with deep, dark red lesions. Full analysis set - rescue (FAS-RE) included all subjects who met the protocol definition of a flare during the DB phase and received at least one dose of rescue treatment. Rescue baseline was defined as the last measurement collected between last dose of blinded treatment and Day 1 of rescue treatment. Here 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint and 'n' signifies subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Rescue Baseline, Rescue Weeks 2, 4, 8 and 12

End point values	PF-04965842 200 mg Rescue Period			
Subject group type	Reporting group			
Number of subjects analysed	342			
Units: percentage of subjects				
number (confidence interval 95%)				
Rescue Week 2 (n= 332)	30.7 (25.8 to 35.7)			
Rescue Week 4 (n= 337)	54.6 (49.3 to 59.9)			
Rescue Week 8 (n= 342)	60.2 (55.0 to 65.4)			
Rescue Week 12 (n= 337)	64.1 (59.0 to 69.2)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Rescue Baseline in Total Eczema Area and Severity Index (EASI) Score at Rescue Weeks 2, 4, 8 and 12: Rescue Period

End point title	Change From Rescue Baseline in Total Eczema Area and Severity Index (EASI) Score at Rescue Weeks 2, 4, 8 and 12: Rescue Period

End point description:

EASI quantifies severity of subject’s AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin] and lower limbs [including buttocks]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (>0 to <10%), 2 (10 to <30%), 3 (30 to <50%), 4 (50 to <70%), 5 (70 to <90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll). Total EASI score ranged from 0.0 to 72.0, higher scores=greater severity of AD. FAS-RE population analysed. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Rescue Baseline, Rescue Weeks 2, 4, 8 and 12

End point values	PF-04965842 200 mg Rescue Period			
Subject group type	Reporting group			
Number of subjects analysed	348			
Units: units on a scale				
least squares mean (confidence interval 95%)				

Change at Rescue Week 2	-71.1 (-73.7 to -68.5)			
Change at Rescue Week 4	-82.0 (-84.2 to -79.7)			
Change at Rescue Week 8	-86.4 (-88.2 to -84.6)			
Change at Rescue Week 12	-87.3 (-89.4 to -85.3)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving Greater Than or Equal to 4 Points Improvement From Rescue Baseline in Peak Pruritus Numeric Rating Scale (PP-NRS) at Rescue Weeks 2, 4, 8 and 12: Rescue Period

End point title	Percentage of Subjects Achieving Greater Than or Equal to 4 Points Improvement From Rescue Baseline in Peak Pruritus Numeric Rating Scale (PP-NRS) at Rescue Weeks 2, 4, 8 and 12: Rescue Period

End point description:

Subjects were asked to assess their worst itching due to AD over the past 24 hours on an NRS scale ranged from 0 (no itch) to 10 (worst itch imaginable), where higher scores indicated greater severity. FAS-RE included all subjects who met the protocol definition of a flare during the DB phase and received at least one dose of rescue treatment. Rescue baseline was defined as the last measurement collected between last dose of blinded treatment and Day 1 of rescue treatment. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint and 'n' signifies subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Rescue Baseline, Rescue Weeks 2, 4, 8 and 12

End point values	PF-04965842 200 mg Rescue Period			
Subject group type	Reporting group			
Number of subjects analysed	272			
Units: percentage of subjects				
number (confidence interval 95%)				
Rescue Week 2 (n= 272)	56.6 (50.7 to 62.5)			
Rescue Week 4 (n= 250)	63.2 (57.2 to 69.2)			
Rescue Week 8 (n= 253)	67.2 (61.4 to 73.0)			
Rescue Week 12 (n= 153)	56.2 (48.3 to 64.1)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Rescue Baseline in Percent Body Surface Area (BSA) at Rescue Weeks 2, 4, 8 and 12: Rescue Period

End point title	Percent Change From Rescue Baseline in Percent Body Surface Area (BSA) at Rescue Weeks 2, 4, 8 and 12: Rescue Period

End point description:

4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin/genitals) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of subject's hand with fingers in a closed position) fitting in affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Overall % BSA for an individual % BSA of all 4 body regions, ranged from 0 to 100%, with higher values representing greater severity of AD. FAS-RE analysed. Rescue baseline was defined as the last measurement collected between last dose of blinded treatment and Day 1 of rescue treatment. Number of Subjects Analysed = subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Rescue Baseline, Rescue Weeks 2, 4, 8 and 12

End point values	PF-04965842 200 mg Rescue Period			
Subject group type	Reporting group			
Number of subjects analysed	348			
Units: percent change in BSA				
least squares mean (confidence interval 95%)				
Change at Rescue Week 2	-62.8 (-66.0 to -59.6)			
Change at Rescue Week 4	-76.4 (-79.1 to -73.7)			
Change at Rescue Week 8	-82.1 (-84.5 to -79.6)			
Change at Rescue Week 12	-83.3 (-86.0 to -80.5)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Rescue Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analog Scale (VAS) Score of Itch and Sleep Loss at Rescue Weeks 2, 4, 8 and 12: Rescue Period

End point title	Percent Change From Rescue Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analog Scale (VAS) Score of Itch and Sleep Loss at Rescue Weeks 2, 4, 8 and 12: Rescue Period

End point description:

SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing;

excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by subject/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7*B/2+C; range (0-103); higher values=worse outcome. FAS-RE analysed. Number of Subjects Analysed = subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Rescue Baseline, Rescue Weeks 2, 4, 8 and 12

End point values	PF-04965842 200 mg Rescue Period			
Subject group type	Reporting group			
Number of subjects analysed	347			
Units: percent change in SCORAD VAS score				
least squares mean (confidence interval 95%)				
Pruritus VAS: Change at Rescue Week 2	-57.3 (-61.7 to -52.9)			
Pruritus VAS: Change at Rescue Week 4	-67.5 (-71.3 to -63.7)			
Pruritus VAS: Change at Rescue Week 8	-68.6 (-73.6 to -63.7)			
Pruritus VAS: Change at Rescue Week 12	-67.3 (-72.8 to -61.8)			
Sleep Loss VAS: Change at Rescue Week 2	-62.5 (-69.1 to -55.9)			
Sleep Loss VAS: Change at Rescue Week 4	-72.4 (-78.6 to -66.3)			
Sleep Loss VAS: Change at Rescue Week 8	-75.8 (-82.0 to -69.5)			
Sleep Loss VAS: Change at Rescue Week 12	-74.5 (-81.4 to -67.5)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With 50% Improvement in Scoring Atopic Dermatitis (SCORAD) From Rescue Baseline at Rescue Weeks 2, 4, 8 and 12: Rescue Period

End point title	Percentage of Subjects With 50% Improvement in Scoring Atopic Dermatitis (SCORAD) From Rescue Baseline at Rescue Weeks 2, 4, 8 and 12: Rescue Period

End point description:

SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by subject/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss,

higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7*B/2+C; range (0-103); higher values=worse outcome. FAS-RE analysed. Number of Subjects Analysed = subjects evaluable for this endpoint and n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Rescue Baseline, Rescue Weeks 2, 4, 8 and 12

End point values	PF-04965842 200 mg Rescue Period			
Subject group type	Reporting group			
Number of subjects analysed	339			
Units: percentage of subjects				
number (confidence interval 95%)				
Rescue Week 2 (n= 331)	55.0 (49.6 to 60.3)			
Rescue Week 4 (n= 339)	76.1 (71.6 to 80.6)			
Rescue Week 8 (n= 338)	79.6 (75.3 to 83.9)			
Rescue Week 12 (n= 337)	79.8 (75.5 to 84.1)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With 75% Improvement in Scoring Atopic Dermatitis (SCORAD) From Rescue Baseline at Rescue Weeks 2, 4, 8 and 12: Rescue Period

End point title	Percentage of Subjects With 75% Improvement in Scoring Atopic Dermatitis (SCORAD) From Rescue Baseline at Rescue Weeks 2, 4, 8 and 12: Rescue Period

End point description:

SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by subject/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7*B/2+C; range (0-103); higher values=worse outcome. FAS-RE analysed. Number of Subjects Analysed = subjects evaluable for this endpoint and n=subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Rescue Baseline, Rescue Weeks 2, 4, 8 and 12

End point values	PF-04965842 200 mg Rescue Period			
Subject group type	Reporting group			
Number of subjects analysed	339			
Units: percentage of subjects				
number (confidence interval 95%)				
Rescue Week 2 (n= 331)	16.9 (12.9 to 21.0)			
Rescue Week 4 (n= 339)	33.9 (28.9 to 39.0)			
Rescue Week 8 (n= 338)	44.4 (39.1 to 49.7)			
Rescue Week 12 (n= 337)	45.4 (40.1 to 50.7)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving Patient Global Assessment (PtGA) Response of 'Clear (0)' or 'Almost Clear (1)' and Greater Than or Equal to 2 Points Improvement From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point title	Percentage of Subjects Achieving Patient Global Assessment (PtGA) Response of 'Clear (0)' or 'Almost Clear (1)' and Greater Than or Equal to 2 Points Improvement From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

Subject responded to the following question: "Overall, how would you describe your Atopic Dermatitis right now?" on a 5-point scale: 0= clear; 1= almost clear; 2= mild; 3= moderate; and 4= severe. Higher scores indicated more severity. FAS-RA included as all subjects who were randomised at Week 12 and received at least 1 dose of study medication within DB phase. Here 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint and 'n' signifies subjects evaluable for the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	254	262	259	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 12 (n= 253, 262, 258)	61.7 (55.7 to 67.7)	64.5 (58.7 to 70.3)	59.7 (53.7 to 65.7)	
Week 16 (n= 254, 262, 259)	5.9 (3.0 to 8.8)	29.8 (24.2 to 35.3)	48.3 (42.2 to 54.3)	
Week 28 (n= 253, 259, 256)	6.3 (3.3 to 9.3)	30.9 (25.3 to 36.5)	46.9 (40.8 to 53.0)	
Week 40 (n= 252, 257, 250)	7.5 (4.3 to 10.8)	26.1 (20.7 to 31.4)	42.0 (35.9 to 48.1)	

Week 52 (n= 251, 256, 247)	7.6 (4.3 to 10.8)	25.8 (20.4 to 31.1)	39.7 (33.6 to 45.8)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	516
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4815 [86]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.3
upper limit	11.3

Notes:

[86] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	513
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6748 [87]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	-1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.3
upper limit	6.6

Notes:

[87] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	521
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	-5.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.4
upper limit	3.2

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	516
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [88]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	24
Confidence interval	
level	95 %
sides	2-sided
lower limit	17.8
upper limit	30.3

Notes:

[88] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	513
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [89]

Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	42.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	35.6
upper limit	49

Notes:

[89] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	521
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	18.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.2
upper limit	26.6

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	516
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [90]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	24.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.2
upper limit	31

Notes:

[90] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	513
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [91]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	40.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	33.7
upper limit	47.3

Notes:

[91] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	521
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	15.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.6
upper limit	24.1

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB

Number of subjects included in analysis	516
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [92]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	18.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.6
upper limit	25.1

Notes:

[92] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	513
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [93]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	34.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	27.6
upper limit	41.5

Notes:

[93] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: Difference in percentage and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	521
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	15.6
Confidence interval	
level	95 %
sides	2-sided

lower limit	7.5
upper limit	23.7

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	516
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [94]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	18.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.4
upper limit	25

Notes:

[94] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage (PF-04965842 - Placebo) and CI for difference were calculated based on the weighted average of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	513
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [95]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in percentage
Point estimate	32.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	25.4
upper limit	39.2

Notes:

[95] - P-value was adjusted by disease severity at baseline and randomisation strata.

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: Difference in percentage and CI for difference were calculated based on the weighted average

of difference for each randomisation stratum and disease severity at baseline using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	521
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Difference in percentage
Point estimate	13.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.6
upper limit	21.7

Secondary: Change From Baseline in Dermatology Life Quality Index (DLQI) Score for Adults at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point title	Change From Baseline in Dermatology Life Quality Index (DLQI) Score for Adults at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

DLQI was a 10-item questionnaire that measures the impact of skin disease. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of subjects. FAS-RA included as all subjects who were randomised at Week 12 and received at least 1 dose of study medication within DB phase. Here 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	217	215	217	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 12	-13.5 (-13.9 to -13.0)	-13.4 (-13.8 to -12.9)	-13.5 (-14.0 to -13.1)	
Change at Week 16	6.9 (6.1 to 7.8)	1.9 (1.2 to 2.5)	0.4 (-0.2 to 1.0)	
Change at Week 28	6.1 (5.0 to 7.1)	2.1 (1.4 to 2.7)	0.9 (0.3 to 1.5)	
Change at Week 40	4.4 (3.0 to 5.7)	2.5 (1.7 to 3.2)	1.1 (0.5 to 1.8)	
Change at Week 52	3.6 (2.1 to 5.0)	2.8 (2.0 to 3.6)	0.9 (0.2 to 1.6)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	432
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7373
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	0.7

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	434
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8092
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.7
upper limit	0.5

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB

Number of subjects included in analysis	432
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	0.4

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	432
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-5.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.1
upper limit	-4

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	434
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-6.6
Confidence interval	
level	95 %
sides	2-sided

lower limit	-7.6
upper limit	-5.5

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	432
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-1.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.4
upper limit	-0.6

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	432
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.3
upper limit	-2.7

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	434
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-5.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.4
upper limit	-3.9

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	432
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.1
upper limit	-0.3

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	432
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.015
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1.9
Confidence interval	
level	95 %

sides	2-sided
lower limit	-3.5
upper limit	-0.4

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	434
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-3.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.7
upper limit	-1.7

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	432
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.3
upper limit	-0.3

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease

severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	432
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3616
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.4
upper limit	0.9

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	434
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0012
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-2.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.3
upper limit	-1.1

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	432
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference

Point estimate	-1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3
upper limit	-0.8

Secondary: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Score for Adolescents at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point title	Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Score for Adolescents at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

CDLQI is a 10-item questionnaire that measures the impact of skin disease on adolescents (aged 12-17 years) quality of life over the last week. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all , 1 = only a little, 2 = quite a lot, 3 = very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give CDLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children. FAS-RA included as all subjects who were randomised at Week 12 and received at least 1 dose of study medication within DB phase. Here 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	49	48	47	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 12	-9.8 (-10.6 to -8.9)	-9.2 (-10.0 to -8.3)	-9.3 (-10.2 to -8.5)	
Change at Week 16	5.9 (4.4 to 7.5)	1.7 (0.5 to 2.9)	-0.3 (-1.4 to 0.8)	
Change at Week 28	1.5 (-0.2 to 3.2)	1.6 (0.6 to 2.6)	0.4 (-0.5 to 1.3)	
Change at Week 40	2.1 (0.3 to 3.8)	1.7 (0.7 to 2.7)	0.0 (-0.9 to 0.9)	
Change at Week 52	2.3 (0.3 to 4.4)	1.3 (0.0 to 2.6)	0.4 (-0.6 to 1.4)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 12: The LSM differences between treatment groups were derived from the statistical model.

MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3339
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.6
upper limit	1.8

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4653
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	1.7

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	95
Analysis specification	Pre-specified
Analysis type	superiority

Parameter estimate	LSM difference
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	1.1

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-4.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.2
upper limit	-2.3

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-6.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.2
upper limit	-4.3

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB
Statistical analysis description: Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	95
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.6
upper limit	-0.3

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB
Statistical analysis description: Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9083
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.8
upper limit	2.1

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB
Statistical analysis description: Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB

Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2439
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3
upper limit	0.8

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	95
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.6
upper limit	0.1

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7405
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided

lower limit	-2.4
upper limit	1.7

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.041
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.1
upper limit	-0.1

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	95
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.1
upper limit	-0.4

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4026
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.5
upper limit	1.4

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0944
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.2
upper limit	0.3

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	95
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.9
Confidence interval	
level	95 %

sides	2-sided
lower limit	-2.5
upper limit	0.7

Secondary: Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety Scale at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point title	Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety Scale at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

HADS: subject rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale, both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-A: sum of all 7 items resulted in score range of 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicating greater severity of anxiety. FAS-RA included as all subjects who were randomised at Week 12 and received at least 1 dose of study medication within DB phase. Here 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	266	263	264	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 12	-2.7 (-3.0 to -2.3)	-2.6 (-2.9 to -2.3)	-2.6 (-2.9 to -2.3)	
Change at Week 16	1.4 (1.0 to 1.8)	0.3 (0.0 to 0.6)	0.0 (-0.3 to 0.3)	
Change at Week 28	1.0 (0.5 to 1.5)	0.4 (0.1 to 0.7)	0.1 (-0.2 to 0.4)	
Change at Week 40	1.0 (0.4 to 1.6)	0.4 (0.1 to 0.8)	0.1 (-0.3 to 0.4)	
Change at Week 52	0.8 (0.2 to 1.4)	0.4 (0.1 to 0.8)	0.2 (-0.1 to 0.5)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	529
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7556
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	0.6

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7484
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	0.6

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	527
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	0
Confidence interval	
level	95 %

sides	2-sided
lower limit	-0.5
upper limit	0.5

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	529
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6
upper limit	-0.6

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.9
upper limit	-0.9

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	527
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.7
upper limit	0.1

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	529
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0242
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	-0.1

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0012
Method	Mixed models analysis
Parameter estimate	LSM difference

Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	-0.4

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	527
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.6
upper limit	0.1

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	529
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.124
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	0.2

	Placebo DB vs PF-04965842 200mg DB

Statistical analysis title	
Statistical analysis description:	
Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0107
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6
upper limit	-0.2

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB
Statistical analysis description:	
Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	527
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	0.1

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB
Statistical analysis description:	
Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	529
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3139

Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1
upper limit	0.3

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0853
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	0.1

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 200mg DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	527
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.7
upper limit	0.2

Secondary: Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Depression Scale at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point title	Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Depression Scale at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

HADS: subject rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-A scale and HADS-D scale, both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-D: sum of all 7 items resulted in score range of 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicating greater severity of depression symptoms. FAS-RA included as all subjects who were randomised at Week 12 and received at least 1 dose of study medication within DB phase. Here 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	266	263	264	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 12	-2.0 (-2.3 to -1.7)	-1.6 (-1.9 to -1.3)	-1.7 (-2.0 to -1.4)	
Change at Week 16	1.4 (1.0 to 1.8)	0.0 (-0.3 to 0.3)	0.0 (-0.2 to 0.3)	
Change at Week 28	0.7 (0.2 to 1.1)	0.3 (0.0 to 0.5)	0.1 (-0.2 to 0.4)	
Change at Week 40	0.8 (0.2 to 1.4)	-0.1 (-0.4 to 0.3)	0.2 (-0.1 to 0.5)	
Change at Week 52	0.4 (-0.1 to 0.9)	-0.1 (-0.4 to 0.2)	0.1 (-0.2 to 0.3)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	529
Analysis specification	Pre-specified

Analysis type	superiority
P-value	= 0.0674
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	0.8

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1437
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	0.7

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	527
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	0.3

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB
Statistical analysis description: Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	529
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.8
upper limit	-0.9

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB
Statistical analysis description: Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.8
upper limit	-0.9

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB
Statistical analysis description: Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	527
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	0.4

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	529
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1136
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	0.1

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0276
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.6
Confidence interval	
level	95 %

sides	2-sided
lower limit	-1.1
upper limit	-0.1

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB
Statistical analysis description:	
Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	527
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	0.2

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB
Statistical analysis description:	
Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	529
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0108
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.5
upper limit	-0.2

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB
Statistical analysis description:	
Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease	

severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0677
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	0

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	527
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	0.7

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	529
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.132
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.5
Confidence interval	

level	95 %
sides	2-sided
lower limit	-1.1
upper limit	0.1

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB
Statistical analysis description:	
Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2975
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.9
upper limit	0.3

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB
Statistical analysis description:	
Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	527
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	0.6

Secondary: Change From Baseline in Patient Oriented Eczema Measure (POEM) Score at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point title	Change From Baseline in Patient Oriented Eczema Measure

	(POEM) Score at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

POEM was a 7-item subject reported outcome (PRO) measure used to assess the impact of AD (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) over the past week. Each item is scored as following: no days = 0, 1-2 days = 1, 3-4 days = 2, 5-6 days = 3 and, every day = 4. The score ranges from 0 to 28, where higher score indicated greater severity. FAS-RA included as all subjects who were randomised at Week 12 and received at least 1 dose of study medication within DB phase. Here, 'Number of Subjects Analysed' signifies number of subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	265	263	263	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 12	-15.4 (-16.0 to -14.8)	-15.8 (-16.4 to -15.2)	-15.4 (-16.0 to -14.8)	
Change at Week 16	9.8 (8.9 to 10.7)	3.7 (3.0 to 4.4)	0.6 (-0.1 to 1.2)	
Change at Week 28	8.3 (6.9 to 9.7)	3.7 (2.8 to 4.6)	1.6 (0.8 to 2.4)	
Change at Week 40	7.4 (5.8 to 9.1)	4.8 (3.9 to 5.8)	1.9 (1.1 to 2.8)	
Change at Week 52	7.3 (5.4 to 9.2)	4.9 (3.8 to 6.0)	2.2 (1.3 to 3.2)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3531
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	0.4

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB
Statistical analysis description: Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9282
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	0.9

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB
Statistical analysis description: Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	526
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	1.3

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB
Statistical analysis description: Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB

Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-6.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.3
upper limit	-5

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-9.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.3
upper limit	-8.1

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	526
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-3.1
Confidence interval	
level	95 %
sides	2-sided

lower limit	-4
upper limit	-2.1

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-4.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.2
upper limit	-2.9

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-6.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.3
upper limit	-5.1

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: The LSM differences between treatment groups were derived from the statistical model.

MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	526
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.3
upper limit	-0.9

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0082
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-2.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.5
upper limit	-0.7

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-5.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.4
upper limit	-3.6

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	526
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-2.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.2
upper limit	-1.6

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0313
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-2.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.5
upper limit	-0.2

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-5.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.1
upper limit	-3

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	526
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-2.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.1
upper limit	-1.3

Secondary: Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) Score at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point title	Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) Score at Weeks 12, 16, 28, 40 and 52: Double-blind Period

End point description:

PSAAD is a daily subject reported symptom electronic diary. Subjects rated their symptoms of AD over the past 24 hours, using 11 items (itchy skin, painful skin, dry skin, flaky skin, cracked skin, bumpy skin, red skin, discolored skin [darker or lighter], bleeding from skin, seeping or oozing fluid from skin [other than blood], and skin swelling). Subject had to think about all the areas of their body affected by their skin condition and chose the number that best described their experience for each of the 11 items, from 0 (no symptoms) to 10 (extreme symptoms), higher scores signified worse skin condition. Total PSAAD score = arithmetic mean of 11 items, 0 (no symptoms) to 10 (extreme symptoms), where higher score = worse skin condition. FAS-RA included as all subjects who were randomised at Week 12 and received at least 1 dose of study medication within DB phase. Here 'Number of Subjects Analysed'

signifies number of subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Baseline, Weeks 12, 16, 28, 40 and 52

End point values	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB	PF-04965842 200mg OL to 200mg DB	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	254	260	254	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 12	-4.1 (-4.3 to -3.9)	-4.2 (-4.4 to -4.0)	-4.2 (-4.4 to -4.0)	
Change at Week 16	2.1 (1.9 to 2.2)	0.8 (0.6 to 0.9)	0.1 (-0.1 to 0.3)	
Change at Week 28	2.3 (2.0 to 2.6)	1.0 (0.8 to 1.2)	0.1 (-0.1 to 0.3)	
Change at Week 40	2.0 (1.7 to 2.4)	1.0 (0.8 to 1.3)	0.3 (0.0 to 0.5)	
Change at Week 52	1.9 (1.5 to 2.3)	1.2 (0.9 to 1.4)	0.2 (0.0 to 0.5)	

Statistical analyses

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	514
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4832
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	0.2

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: The LSM differences between treatment groups were derived from the statistical model.

MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6553
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	0.2

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 12: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	514
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	0.3

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	514
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1.3

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.5
upper limit	-1.1

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	-1.7

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 16: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	514
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.9
upper limit	-0.4

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	514
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.7
upper limit	-1

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-2.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	-1.8

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 28: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	514
Analysis specification	Pre-specified
Analysis type	superiority

Parameter estimate	LSM difference
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1
upper limit	-0.5

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB

Statistical analysis description:

Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	514
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	-0.6

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	-1.4

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB
Statistical analysis description: Week 40: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	514
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1
upper limit	-0.5

Statistical analysis title	Placebo DB vs PF-04965842 100mg DB
Statistical analysis description: Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 100mg DB
Number of subjects included in analysis	514
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	-0.3

Statistical analysis title	Placebo DB vs PF-04965842 200mg DB
Statistical analysis description: Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.	
Comparison groups	PF-04965842 200mg OL to Placebo DB v PF-04965842 200mg OL to 200mg DB

Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM difference
Point estimate	-1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	-1.2

Statistical analysis title	PF-04965842 100mg DB vs PF-04965842 200mg DB

Statistical analysis description:

Week 52: The LSM differences between treatment groups were derived from the statistical model. MMRM contained fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, randomisation strata, baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200mg OL to 100mg DB v PF-04965842 200mg OL to 200mg DB
Number of subjects included in analysis	514
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LSM difference
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	-0.6

Adverse events information

Timeframe for reporting adverse events:

From screening up to 28 days after last dose of study treatment (maximum up to week 56)

Adverse event reporting additional description:

Safety analysis set included all subjects who received at least 1 dose of study medication.

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	23.0

Reporting groups

Reporting group title	PF-04965842 200mg OL

Reporting group description:

Subjects received 12 weeks induction treatment of 200 milligram (mg) oral tablets (each tablet of 100 mg) PF-04965842 QD during an OL run-in period. Responders at the end of the 12-week open-label run-in period entered the 40 week, double-blind, maintenance treatment period. Responder criteria was defined as a) achieving an IGA of clear (0) or almost clear (1) (on a 5-point scale), b) a reduction from IGA baseline of greater than or equal to (>= 2) points, and c) reaching an EASI-75 response compared to baseline. Baseline was defined as the IGA score and EASI score obtained prior to dosing on Day 1. Non-responders had a choice to enroll into the PF-04965842 LTE study B7451015 (NCT03422822) otherwise, they were permanently discontinued from treatment and were followed-up for 4-week in this study.

Reporting group title	PF-04965842 200mg OL to Placebo DB

Reporting group description:

Responders from open-label run-in period received two placebo tablets matched to PF-04965842 orally QD during DB period for up to 40 weeks. Subjects who met the protocol defined flare criteria entered an open-label rescue period. Flare was defined as a loss of at least 50 % of the EASI response at Week 12 and an IGA score of 2 or higher.

Reporting group title	PF-04965842 200mg OL to 100mg DB

Reporting group description:

Responders from open-label run-in period received a tablet of 100 mg PF-04965842 and a tablet of matching placebo orally QD during DB period for up to 40 weeks. Subjects who met the protocol defined flare criteria entered an open-label rescue period. Flare was defined as a loss of at least 50% of the EASI response at Week 12 and an IGA score of 2 or higher.

Reporting group title	PF-04965842 200mg OL to 200mg DB

Reporting group description:

Responders from open-label run-in period received 200 mg PF-04965842 (2 tablets of 100 mg each) orally QD during DB period for up to 40 weeks. Subjects who met the protocol defined flare criteria entered an open-label rescue period. Flare was defined as a loss of at least 50 % of the EASI response at Week 12 and an IGA score of 2 or higher.

Reporting group title	PF-04965842 200 mg Rescue Period

Reporting group description:

Subjects who met the protocol defined flare criteria in DB period received 200 mg PF-04965842 (2 tablets of 100 mg each) orally QD during OL Rescue Period for up to 12 weeks. After completing the 12-week rescue period, subjects had the choice to enter the LTE study B7451015 (NCT03422822), if eligible. Subjects who discontinued early from treatment, or who were otherwise ineligible for the LTE study entered were followed-up for 4 week in this study.

Serious adverse events	PF-04965842 200mg OL	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB
Total subjects affected by serious adverse events			
subjects affected / exposed	20 / 1233 (1.62%)	2 / 267 (0.75%)	4 / 265 (1.51%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events	1	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma gastric			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Papillary thyroid cancer			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	1 / 265 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Adnexa uteri cyst			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metrorrhagia			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural			

complications			
Humerus fracture			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ligament injury			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meniscus injury			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple fractures			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin laceration			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Vitello-intestinal duct remnant			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Microcytic anaemia			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0

deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Cataract			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal detachment			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal vein thrombosis			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	1 / 265 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulcerative keratitis			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	0 / 265 (0.00%)

occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Ureterolithiasis			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	3 / 1233 (0.24%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Haemarthrosis			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myositis			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypokalaemia			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess neck			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0

deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	2 / 1233 (0.16%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eczema herpeticum			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	1 / 265 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal viral infection			
subjects affected / exposed	0 / 1233 (0.00%)	1 / 267 (0.37%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis E			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periodontitis			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonsillar abscess			
subjects affected / exposed	0 / 1233 (0.00%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pharyngitis			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 1233 (0.08%)	1 / 267 (0.37%)	1 / 265 (0.38%)
occurrences causally related to treatment / all	1 / 1	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
subjects affected / exposed	1 / 1233 (0.08%)	0 / 267 (0.00%)	0 / 265 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	PF-04965842 200mg OL to 200mg DB	PF-04965842 200 mg Rescue Period	
Total subjects affected by serious adverse events			
subjects affected / exposed	13 / 266 (4.89%)	4 / 351 (1.14%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma gastric			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary thyroid cancer			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	1 / 266 (0.38%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest pain			

subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Adnexa uteri cyst			
subjects affected / exposed	1 / 266 (0.38%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metrorrhagia			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Humerus fracture			
subjects affected / exposed	1 / 266 (0.38%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament injury			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus injury			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple fractures			
subjects affected / exposed	1 / 266 (0.38%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin laceration			
subjects affected / exposed	1 / 266 (0.38%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Upper limb fracture			
subjects affected / exposed	1 / 266 (0.38%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Vitello-intestinal duct remnant			
subjects affected / exposed	1 / 266 (0.38%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Microcytic anaemia			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Seizure			
subjects affected / exposed	1 / 266 (0.38%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Cataract			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal detachment			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vein thrombosis			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	

deaths causally related to treatment / all	0 / 0	0 / 0	
Ulcerative keratitis			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 266 (0.38%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	1 / 266 (0.38%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Ureterolithiasis			
subjects affected / exposed	0 / 266 (0.00%)	1 / 351 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	0 / 266 (0.00%)	2 / 351 (0.57%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Haemarthrosis			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myositis			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis			

subjects affected / exposed	1 / 266 (0.38%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hypokalaemia			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abscess neck			
subjects affected / exposed	1 / 266 (0.38%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	1 / 266 (0.38%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eczema herpeticum			
subjects affected / exposed	1 / 266 (0.38%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal viral infection			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis E			

subjects affected / exposed	1 / 266 (0.38%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periodontitis			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonsillar abscess			
subjects affected / exposed	1 / 266 (0.38%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			
subjects affected / exposed	0 / 266 (0.00%)	1 / 351 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			
subjects affected / exposed	0 / 266 (0.00%)	0 / 351 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	PF-04965842 200mg OL	PF-04965842 200mg OL to Placebo DB	PF-04965842 200mg OL to 100mg DB
Total subjects affected by non-serious adverse events			
subjects affected / exposed	466 / 1233 (37.79%)	91 / 267 (34.08%)	72 / 265 (27.17%)
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	43 / 1233 (3.49%)	1 / 267 (0.37%)	6 / 265 (2.26%)
occurrences (all)	43	1	7

Nervous system disorders Headache subjects affected / exposed occurrences (all)	119 / 1233 (9.65%) 142	1 / 267 (0.37%) 1	1 / 265 (0.38%) 1
Gastrointestinal disorders Nausea subjects affected / exposed occurrences (all)	199 / 1233 (16.14%) 241	1 / 267 (0.37%) 1	2 / 265 (0.75%) 4
Skin and subcutaneous tissue disorders Acne subjects affected / exposed occurrences (all)	68 / 1233 (5.52%) 69	0 / 267 (0.00%) 0	5 / 265 (1.89%) 5
Dermatitis atopic subjects affected / exposed occurrences (all)	45 / 1233 (3.65%) 46	83 / 267 (31.09%) 85	51 / 265 (19.25%) 54
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	77 / 1233 (6.24%) 78	5 / 267 (1.87%) 5	10 / 265 (3.77%) 12
Upper respiratory tract infection subjects affected / exposed occurrences (all)	63 / 1233 (5.11%) 70	6 / 267 (2.25%) 7	8 / 265 (3.02%) 9

Non-serious adverse events	PF-04965842 200mg OL to 200mg DB	PF-04965842 200 mg Rescue Period	
Total subjects affected by non-serious adverse events subjects affected / exposed	81 / 266 (30.45%)	74 / 351 (21.08%)	
Investigations Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	14 / 266 (5.26%) 16	9 / 351 (2.56%) 11	
Nervous system disorders Headache subjects affected / exposed occurrences (all)	7 / 266 (2.63%) 11	12 / 351 (3.42%) 13	
Gastrointestinal disorders			

Nausea			
subjects affected / exposed	8 / 266 (3.01%)	12 / 351 (3.42%)	
occurrences (all)	9	12	
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	8 / 266 (3.01%)	7 / 351 (1.99%)	
occurrences (all)	9	7	
Dermatitis atopic			
subjects affected / exposed	33 / 266 (12.41%)	13 / 351 (3.70%)	
occurrences (all)	33	15	
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	18 / 266 (6.77%)	17 / 351 (4.84%)	
occurrences (all)	20	20	
Upper respiratory tract infection			
subjects affected / exposed	8 / 266 (3.01%)	21 / 351 (5.98%)	
occurrences (all)	8	23	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported